In a retrospective analysis, researchers compared survival outcomes and prognostic factors between patients with advanced-stage epithelial ovarian cancer who underwent hyperthermic intraperitoneal...
In a retrospective analysis, researchers compared survival outcomes and prognostic factors between patients with advanced-stage epithelial ovarian cancer who underwent hyperthermic intraperitoneal...
In a retrospective analysis, researchers compared survival outcomes and prognostic factors between patients with advanced-stage epithelial ovarian cancer who underwent hyperthermic intraperitoneal...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
A real-world retrospective study found that adding GLP-1 receptor agonists to hormone therapy may reduce endometrial cancer risk in women with benign uterine or endometrial hyperplasia. This study was...
